Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients

Journal of Ovarian Research

Jolanta Kupryjanczyk⁵  Beata Osuch³  Piotr Sobiczewski⁶  Tomasz Napiorkowski¹  Magdalena Murawska⁴  Radoslaw Madry²  Lukasz Szafron⁵  Iwona K Rzepecka⁵  Alina Rembiszewska⁵  Anna Felisiak-Golabek⁵ 

[1] Department of Anaesthesiology and Intensive Care, The Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland;Chair of Gynaecologic Oncology, Medical University, Poznan, Poland;Chair and Department of Obstetrics, Gynaecology and Oncology, IInd Faculty of Medicine, Warsaw Medical University and Brodnowski Hospital, Warsaw, Poland;Department of Biostatistics, The Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland;Department of Molecular Pathology, The Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland;Department of Gynaecologic Oncology, The Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland

关键词: TP53;    taxol;    survivin;    ovarian cancer;   

Others  :  824409
DOI  :  10.1186/1757-2215-4-20

 received in 2011-06-27, accepted in 2011-11-10,  发布年份 2011

【 摘 要 】

Background

Survivin is an inhibitor of apoptosis and a regulator of mitotic progression. TP53 protein is a negative transcriptional regulator of survivin. The aim of our study was to evaluate the clinical significance of survivin expression in advanced stages ovarian cancer with respect to the TP53 status.

Methods

Survivin and TP53 expression was evaluated immunohistochemically in 435 archival samples of ovarian carcinomas (244 patients were treated with platinum/cyclophosphamide-PC/PAC; 191-with taxane-platinum (TP) agents). Univariate and multivariate statistical analyses were performed in patients groups divided according to the administered chemotherapeutic regimen, and in subgroups with and without TP53 accumulation (TP53+ and TP53-, respectively).

Results

Nuclear and cytoplasmic survivin expression was observed in 92% and 74% of the carcinomas, respectively. In patients treated with TP, high nuclear survivin expression decreased the risk of disease recurrence and death, and increased the probability of high platinum sensitivity (p < 0.01), but only in the TP53(+) group, and not in the TP53(-) group.

Conclusions

It appears that TP53 status determines the clinical importance of nuclear survivin expression in taxane-platinum treated ovarian cancer patients.

【 授权许可】

   
2011 Felisiak-Golabek et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Ambrosini G, Adida C, Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997, 3:917-921.
• [2]Ryan BM, O'Donovan N, Duffy MJ: Survivin: a new target for anti-cancer therapy. Cancer Treat Rev 2009, 35:553-562.
• [3]Duffy MJ, O'Donovan N, Brennan DJ, Gallagher WM, Ryan BM: Survivin: a promising tumour biomarker. Cancer Lett 2007, 249:49-60.
• [4]Li F, Yang J, Ramnath N, Javle MM, Tan D: Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer 2005, 114:509-512.
• [5]McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996, 334:1-6.
• [6]Trimble EL, Wright J, Christian MC: Treatment of platinum-resistant ovarian cancer. Expert Opin Pharmacother 2001, 2:1299-1306.
• [7]Stuart GCE: First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer. Gynecol Oncol 2003, 90:8-15.
• [8]Kupryjanczyk J, Kraszewska E, Ziolkowska-Seta I, Madry R, Timorek A, Markowska J, Stelmachow J, Bidzinski M: TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: a non-randomized retrospective study. BMC Cancer 2008, 8:1-13. BioMed Central Full Text
• [9]Fan W: Possible mechanisms of paclitaxel-induced apoptosis. Biochem Pharmacol 1999, 57:1215-1221.
• [10]Kelling J, Sullivan K, Wilson L, Jordan MA: Suppression of centromere dynamics by taxol in living osteosarcoma cells. Cancer Res 2003, 63:2794-2801.
• [11]Skoufias DA, Mollinari C, Lacroix FB, Margolis RL: Human survivin is a kinetochore-associated passenger protein. J Cell Biol 2000, 151:1575-1581.
• [12]Bergstralh DT, Ting JP-Y: Microtubule stabilizing agents: their molecular signaling consequences and the potential for enhancement by drug combination. Cancer Treat Rev 2006, 32:166-179.
• [13]Vagnarelli P, Earnshaw WC: Chromosomal passengers: the four-dimensional regulation of mitotic events. Chromosoma 2004, 113:211-222.
• [14]Carvalho A, Carmena M, Sambade C, Earnshaw WC, Wheatley SP: Survivin is required for stable checkpoint activation in taxol-treated HeLa cells. J Cell Sci 2003, 116:2987-2998.
• [15]Zhou J, O'Brate A, Zelnak A, Giannakakou P: Survivin deregulation in beta-tubulin mutant ovarian cancer cells underlies their compromised mitotic response to taxol. Cancer Res 2004, 64:8708-8714.
• [16]Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J, Altieri DC: Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 1998, 152:43-49.
• [17]Fukuda S, Pelus LM: Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther 2006, 5:1087-1098.
• [18]Ferrandina G, Legge F, Martinelli E, Ranelletti FO, Zannoni GF, Lauriola L, Gessi M, Gallotta V, Scambia G: Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters. Br J Cancer 2005, 92:271-277.
• [19]Athanassiadou P, Grapsa D, Athanassiades P, Gonidi M, Athanassiadou A-M, Tsipis A, Patsouris E: The prognostic significance of COX-2 and survivin expression in ovarian cancer. Pathol Res Pract 2008, 204:241-249.
• [20]Engels K, Knauer SK, Loibl S, Fetz V, Harter P, Schweitzer A, Fisseler-Eckhoff A, Kommoss F, Hanker L, Nekljudova V, Hermanns I, Kleinert H, Mann W, du Bois A, Stauber RH: NO signalling confers cytoprotectivity through the survivin network in ovarian carcinomas. Cancer Res 2008, 68:5159-5166.
• [21]Smith-Sorensen B, Kaern J, Holm R, Dorum A, Trope C, Borresen-Dale A-L: Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status. Br J Cancer 1998, 78:375-381.
• [22]Ueno Y, Enomoto T, Otsuki Y, Sugita N, Nakashima R, Yoshino K, Kuragaki C, Ueda Y, Aki T, Ikegami H, Yamazaki M, Ito K, Nagamatsu M, Nishizaki T, Asada M, Kameda T, Wakimoto A, Mizutani T, Yamada T, Murata Y: Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin. Cancer Lett 2006, 241:289-300.
• [23]Kupryjanczyk J, Szymanska T, Madry R, Timorek A, Stelmachow J, Karpinska G, Rembiszewska A, Ziolkowska I, Kraszewska E, Debniak J, Emerich J, Ulanska M, Pluzanska A, Jedryka M, Goluda M, Chudecka-Glaz A, Rzepka-Gorska I, Klimek M, Urbanski K, Breborowicz J, Zielinski J, Markowska J: Evaluation of clinical significance of TP53, BCL-2, BAX and MEK 1 expression in 229 ovarian carcinoma treated with platinum-based regimen. Br J Cancer 2003, 88:848-854.
• [24]Kupryjanczyk J, Madry R, Plisiecka-Halasa J, Bar J, Kraszewska E, Ziolkowska I, Timorek A, Stelmachow J, Emerich J, Jedryka M, Pluzanska A, Rzepka-Gorska I, Urbanski K, Zielinski J, Markowska J: TP53 status determines clinical significance of ERBB2 expression in ovarian cancer. Br J Cancer 2004, 91:1916-1923.
• [25]Ziolkowska-Seta I, Madry R, Kraszewska E, Szymanska T, Timorek A, Rembiszewska A, Kupryjanczyk J: TP53, BCL-2 and BAX analysis in 199 ovarian cancer patients treated with taxane-platinum regimens. Gynecol Oncol 2009, 112:179-184.
• [26]Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M: Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002, 277:3247-3257.
• [27]Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR, Nielsen LL, Pickett CB, Liu S: Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002, 21:2613-2622.
• [28]Creasman WJ: Announcement, FIGO stages 1988, revisions. Gynecol Oncol 1989, 35:125-127.
• [29]Tavassoli FA, Devilee P: pathology and genetics of tumours of the breast and female genital organs World Health Organisation classification of tumours. IARC Press Lyon; 2003.
• [30]Barber HR, Sommers SC, Snyder R, Kwon TH: Histologic and nuclear grading and stromal reactions as indices for prognosis in ovarian cancer. Am J Obstet Gynecol 1975, 121:795-807.
• [31]Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981, 47:207-214.
• [32]Christian MC, Trimble EL: Salvage chemotherapy for epithelial ovarian carcinoma. Gynecol Oncol 1994, 55:143-150.
• [33]Dansonka-Mieszkowska A, Ludwig AH, Kraszewska E, Kupryjanczyk J: Geographical variations in TP53 mutational spectrum in ovarian carcinomas. Ann Hum Genet 2006, 70:594-604.
• [34]Ball E, Bond J, Franc B, DeMicco C, Wynford-Thomas D: An immunohistochemical study of p16INK4a expression in multistep thyroid tumourigenesis. Eur J Cancer 2007, 43:194-201.
• [35]Grabowski P, Kuhnel T, Muhr-Wilkenshoff F, Heine B, Stein H, Hopfner M, Germer CT, Scherubl H: Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Br J Cancer 2003, 88:115-119.
• [36]Lu B, Gonzalez A, Massion PP, Shyr Y, Shaktour B, Carbone DP, Hallahan DE: Nuclear survivin as a biomarker for non-small-cell lung cancer. Br J Cancer 2004, 91:537-540.
• [37]Martinez A, Bellosillo B, Bosch F, Ferrer A, Marce S, Villamor N, Ott G, Montserrat E, Campo E, Colomer D: Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. Am J Pathol 2004, 164:501-510.
• [38]Trieb K, Lehner R, Stulnig T, Sulzbacher I, Shroyer KR: Survivin expression in human osteosarcoma is a marker for survival. Eur J Surg Oncol 2002, 29:379-382.
• [39]Kennedy SM, O'Driscoll L, Purcell R, Fitz-simons N, McDermott EW, Hill AD, O'Higgins NJ, Parkinson M, Linehan R, Clynes M: Prognostic importance of survivin in breast cancer. Br J Cancer 2003, 88:1077-1083.
• [40]Knauer SK, Kramer OH, Knosel T, Engels K, Rodel F, Kovacs AF, Dietmaier W, Klein-Hitpass L, Habtemichael N, Schweitzer A, Brieger J, Rodel C, Mann W, Petersen I, Heinzel T, Stauber RH: Nuclear export is essential for the tumour-promoting activity of survivin. FASEB J 2007, 21:207-216.
• [41]Vischioni B, van der Valk P, Span SW, Kruyt FAE, Rodriguez JA, Giaccone G: Nuclear localisation of survivin is a positive prognostic factor for survival in advanced non-small-cell lung cancer. Ann Oncol 2004, 15:1654-1660.
• [42]Zaffaroni N, Pennati M, Colella G, Perego P, Supino R, Gatti L, Pilotti S, Zunino F, Daidone MG: Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. CMLS 2002, 59:1406-1412.
• [43]Fortugno P, Wall NR, Giodini A, O'Connor DS, Plescia J, Padgett KM, Tognin S, Marchisio PC, Altieri DC: Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci 2002, 115:575-585.
• [44]Sudo T, Nitta M, Saya H, Ueno NT: Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res 2004, 64:2502-2508.
• [45]Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998, 396:580-584.
• [46]Giodini A, Kallio MJ, Wall NR, Gorbsky GJ, Tognin S, Marchisio PC, Symons M, Altieri DC: Regulation of microtubule stability and mitotic progression by survivin. Cancer Res 2002, 62:2426-2467.
• [47]Kupryjanczyk J: Why TP53 status does not associate with clinical endpoints in ovarian cancer: facts and hypotheses. Gynecol Oncol 2006, 100:5-7.
• [48]Ludwig AH, Murawska M, Panek G, Timorek A, Kupryjanczyk J: Androgen, progesterone, and FSH receptor polymorphisms in ovarian cancer risk and outcome. Endocr Relat Cancer 2009, 16:1005-1016.
• [49]Jones NA, Turner J, McIlwrath AJ, Brown R, Dive C: Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53. Mol Pharmacol 1998, 53:819-826.
• [50]Lavarino C, Pilotti S, Oggionni M, Gatti L, Perego P, Bresciani G, Pierotti MA, Scambia G, Ferrandina G, Fagotti A, Mangioni C, Lucchini V, Vecchione F, Bolis G, Scarfone G, Zunino F: p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol 2000, 18:3936-3945.
• [51]Gadducci A, Di Cristofano C, Zavaglia M, Giusti L, Menicagli M, Cosio S, Naccarato AG, Genazzani AR, Bevilacqua G, Cavazzana AO: P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel-plus platinum-based chemotherapy and long-term clinical outcome. Anticancer Res 2006, 26:687-693.
• [52]Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW, Galloway DA: Loss of normal p53 function confers sensitisation to taxol by increasing G2/M arrest and apoptosis. Nat Med 1996, 2:72-79.
• [53]Cassinelli G, Supino R, Perego P, Polizzi D, Lanzi C, Pratesi G, Zunino F: A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes. Int J Canacer 2001, 92:738-747.
• [54]Cohen C, Lohmann ChM, Cotsonis G, Lawson D, Santoianni R: Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognosis. Mod Pathol 2003, 16:574-583.
• [55]Lu C-D, Altieri DC, Tanigawa N: Expression of a novel antiapoptosis gene, survivin, correlated with tumour cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 1998, 58:1808-1812.
• [56]Jinfeng M, Kimura W, Sakurai F, Moriya T, Takeshita A, Hirai I: Histopathological study of intraductal papillary mucinous tumour of the pancreas: special reference to the roles of Survivin and p53 in tumourigenesis of IPMT. Int J Gastrointest Cancer 2002, 32:73-81.
• [57]Vegran F, Boidot R, Oudin C, Defrain C, Rebucci M, Lizard-Nacol S: Association of p53 gene alternations with the expression of antiapoptotic survivin splice variants in breast cancer. Oncogene 2007, 26:290-297.